Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 19/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 18/20 | 0.69 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.69 |
| ▸ | PIK3CB | P42338 | 18/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 18/20 | 0.69 |
| ▸ | PRKDC | P78527 | 18/20 | 0.69 |
| ▸ | ABL1 | P00519 | 17/20 | 0.69 |
| ▸ | EGFR | P00533 | 17/20 | 0.69 |
| ▸ | HCK | P08631 | 17/20 | 0.69 |
| ▸ | KDR | P35968 | 17/20 | 0.69 |
| ▸ | MTOR | P42345 | 17/20 | 0.69 |
| ▸ | EPHB4 | P54760 | 16/20 | 0.69 |
| ▸ | PI4KB | Q9UBF8 | 13/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24096758 | 0.92 | PIK3CD (0.69) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29998830 | 0.92 | PIK3CD (0.69) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30320600 | 0.90 | PIK3CD (0.77) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL23997147 | 0.90 | PIK3CD (0.77) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL27088080 | 0.88 | PIK3CD (0.70) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL24096515 | 0.87 | PIK3CD (0.66) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30320504 | 0.87 | PIK3CD (0.66) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL24096530 | 0.86 | SRC (0.66) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5804212 | 0.86 | PIK3CD (0.62) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30320556 | 0.86 | SRC (0.66) | SRCPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021226547-A2 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| CN-1520298-A | Pyrazolopyrimidines as therapeutic agents | �����ʩ���عɷݹ�˾ | 2004-08-11 | — | — | CN | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | SRC 1834/4885PIK3CD 1497/4885PIK3CA 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.